Germany: Atai prices upsized US$225m IPO in the US at US$15 per share

Berlin headquartered Atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, has priced an upsized IPO on Nasdaq of 15 million shares at US$15 per share to raise gross proceeds of US$225m. There is a Greenshoe option of 2.25 million shares. The deal was initially marketed at 14.286…

You must be a HMI Subscriber to view this content.

Subscribe Now »